source
- Epkinly shows 51% PFS boost in frontline DLBCL, may become new standard of careAbbVie and Genmab reported that their bispecific antibody Epkinly achieved a substantial gain in progression‑free survival when added to the standard R‑CHOP regimen in newly diagnosed diffuse large…
- GE HealthCare to buy Sofie Biosciences for $945 million, boosting U.S. PET radiopharma capacityGE HealthCare announced it will acquire Sofie Biosciences for $945 million in cash, aiming to broaden its radiopharmaceutical manufacturing and distribution in the United States. Sofie Biosciences…